Guidelines Development Group
The GDG will follow the GRADE approach in defining the healthcare question of interest (population of interest, interventions to be compared and patient-relevant outcomes- PICO), synthesizing the evidence and developing the recommendations for the Guidelines. This will be carried out within virtual working environments and in meetings organised every three months. The initial draft documents and the final versions before publication are subject of open calls for feedback launched online.
An external contractor, CCIb –Iberoamerican Cochrane Centre, supports the GDG for their tasks from literature review to drafting of recommendations.
Members and external experts
GDG clinical co-chair
Dr. Axel Gräwingholt graduated from Johannes Gutenberg University Mainz, Germany in 1991. He started his career in radiology mainly on MRI and CT. Since 1993 he has been involved in breast cancer diagnosis and when the German screening program started in 2006 he founded a screening unit in Paderborn Germany. He is co-owner of a private institute for radiology in Paderborn.
Since 2009 he was also involved in the development of the cantonal screening program in St. Gall, Switzerland where he was acting head for 2 years and acted as a supervisor for readers and also a consultant in quality control. Since then he has taught many courses in Switzerland for Screening in St. Gall, Bern and Basel. He is still involved in screening programs in Fribourg and Thurgau as a consultant.
In 2014 he started an educational program at the Yerevan Medical State University in Yerevan, Armenia where he was appointed a visiting professor in the department of radiology in June 2015. Apart from that he is also reading mammograms for second opinions for the National Oncology Center in Armenia and the Armenian American Wellness Center in Yerevan, Armenia.
His main work though remains the Screening Unit in Paderborn, Germany.
His doctorate thesis was on evaluation of a regional quality assured screening program in comparison to other screening programs.
He has been a member of a working group for test set development of the ICSN / International Cancer Screening Network.